Close menu
Brain & Behavior
Grants & Prizes
Home
Research
Illness
Addiction
Anxiety Disorders
Attention-Deficit Hyperactivity Disorder (ADHD)
Autism Spectrum Disorder (ASD)
Bipolar Disorder
Borderline Personality Disorder (BPD)
Depression
Eating Disorders
Mental Illness (General)
Obsessive-Compulsive Disorder (OCD)
Post-Traumatic Stress Disorder (PTSD)
Schizophrenia
Suicide Prevention
Other Brain-Related Illnesses
Category
Basic Research
New Technologies
Early Intervention/ Diagnostic Tools
Next Generation Therapies
Blog
Get Involved
Give
Donate Today
Make a Memorial/Tribute Gift
Create an Event/Memorial Page
Find an Event/Memorial Page
Make a Stock/Securities Gift/IRA Charitable Rollover Gift
Donate Cryptocurrency
Get Involved
Other Giving Opportunities
$1 Million Challenge Match
Planned Giving
Research Partners
Donor Advised Funds
Workplace Matching Gifts
Team Up for Research!
Sponsorship Opportunities
Watch
Healthy Minds TV
Meet the Scientist Webinars
Videos
Connect
Ask the Expert
Join Us
Home
Grants
Grant FAQs
BBRF Young Investigator Grants
BBRF Independent Investigator Grants
BBRF Distinguished Investigator Grants
Prizes & Awards
Klerman & Freedman Prizes
Outstanding Achievement Prizes
Lieber Prize for Schizophrenia Research
Maltz Prize for Schizophrenia Research
Colvin Prize for Mood Disorders Research
Ruane Prize for Child and Adolescent Psychiatric Research
Goldman-Rakic Prize for Cognitive Neuroscience Research
The Pardes Humanitarian Prize
Productive Lives Awards
Blog
About Us
Who We Are
Our Impact
FAQs
Media Center
News
Press Releases
Opinion Pieces
In the News
Multimedia Library
Media Kit
Events & Webinars
Team Up for Research! Events
Healthy Minds TV
Contact
Email Signup
Open Menu

Menu

Ketamine: Why Now? How? Where Do We Go from Here?

Tuesday, June 12, 2018, 2:00 pm EDT
Meet the Scientist - June 2018

Can the fast-acting antidepressant ketamine help people with PTSD? Scientists theorize that traumatic stress impairs the integrity of connections between nerve cells in the brain, leading to a variety of often debilitating problems, including those experienced by people with PTSD. Dr. Krystal explores the possibility of restoring damaged neural connections to provide relief for patients.

Watch webinar recording:

Please use #BBRFWebinar when sharing or posting about our Meet the Scientist Webinars on social media.

Sign up for other upcoming webinars.

View past webinar recordings.

Presentation

Download Slide Presentation
Presented by 
John H. Krystal, M.D.
John H. Krystal, M.D.
Yale University School of Medicine

Robert L. McNeil, Jr. Professor of Translational Research and Professor of Psychiatry and of Neuroscience

Chair, Department of Psychiatry,

Chief of Psychiatry and Behavioral Health, Yale-New Haven Hospital

Director, Clinical Neuroscience Division, VA National Center for PTSD

Director: NIAAA Center for the Translational Neuroscience of Alcoholism

Scientific Council Member (Joined 2003)

2019 Colvin Prizewinner for Outstanding Achievement in Mood Disorders Research

2006, 2000 Distinguished Investigator Grant

1997 Independent Investigator Grant

Dr. John H. Krystal is a leading expert in the areas of alcoholism, post-traumatic stress disorder, schizo-phrenia, and depression. His work links psychophar-macology, neuroimaging, molecular genetics, and computational neuroscience to study the neurobi-ology and treatment of these disorders. He is best known for leading the discovery of the rapid antide-pressant effects of ketamine in depressed patients.

In the 1990s, Dr. Krystal’s mentor and colleague, Dr. Dennis Charney, found reason to question the centrality of monoamines to depression. This led them to hypothesize that the signaling mechanisms employed by higher brain centers, particularly glutamate and GABA signaling, might be critical to depression and its treatment.
Moderated by 
Dr. Jeffrey Borenstein, President and CEO of the Brain & Behavior Research Foundation
Read Full Bio
Jeffrey Borenstein, M.D.
Brain & Behavior Research Foundation

President and CEO

Jeffrey Borenstein, M.D., serves as the President & CEO of the Brain & Behavior Research Foundation, the largest private funder of mental health research grants. Dr. Borenstein developed the Emmy-nominated public television program “Healthy Minds,” and serves as host and executive producer of the series. The program, broadcast nationwide, is available online, and focuses on topics in psychiatry in order to educate the public, reduce stigma and offer a message of hope. Dr. Borenstein also serves as Editor-in-Chief of Psychiatric News, the newspaper of the American Psychiatric Association.

Dr. Borenstein is a Fellow of the New York Academy of Medicine and serves as the Chair of the Section of Psychiatry at the Academy. He also has served as the President of the New York State Psychiatric Association. Dr. Borenstein earned his undergraduate degree at Harvard and his medical degree at New York University.